Elecoglipron (AZD5004 / ECC5004)
Metabolic Health · Oral small-molecule GLP-1 agonist
Tier C+
Bottom line
Read Off Label grades Elecoglipron (AZD5004 / ECC5004) as C+ (5.7/10) based on moderate evidence, moderate-high benefit magnitude, and a med-risk safety profile.
AstraZeneca's oral GLP-1 pill (in-licensed from Eccogene in 2023; AZD5004 / ECC5004) — a direct competitor to Lilly's orforglipron in the race for a convenient oral incretin.
Studied, labeled, or reported-use context: Oral once daily — Investigational; not individualized guidance.
What the evidence says
AstraZeneca's oral GLP-1 pill (in-licensed from Eccogene in 2023; AZD5004 / ECC5004) — a direct competitor to Lilly's orforglipron in the race for a convenient oral incretin. Phase 2 VISTA (n=310, 36 wk, obesity/overweight) and SOLSTICE (n=406, type 2 diabetes) both met their primary endpoints. SOLSTICE's full peer-reviewed results published in The Lancet (2026): at 26 weeks, elecoglipron reduced HbA1c by up to -1.88 percentage points (75mg dose) vs -0.15% with placebo; adverse events (mostly GI) occurred in 63-87% of treated participants vs 63% on placebo. VISTA (weight-loss) topline figures remain undisclosed pending peer-reviewed publication. AstraZeneca is advancing the program to Phase 3. Industry-sponsored; peer-reviewed publication pending. Update Jul 2026: Phase 3 program now underway -- the Embold trial (n=4,500) began recruiting Jun 29 2026, with four additional Phase 3 Eluminate trials starting July 2026.
Mechanism
Once-daily oral non-peptide GLP-1 receptor agonist — delivers incretin appetite suppression and glycemic control as a pill rather than an injection
Studied, labeled, or reported dose & route
Oral once daily
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Elecoglipron (AZD5004 / ECC5004)'s effects?
- Read Off Label rates the evidence for Elecoglipron (AZD5004 / ECC5004) as Moderate and the benefit magnitude as moderate-high, producing an overall grade of C+ (5.7/10). AstraZeneca's oral GLP-1 pill (in-licensed from Eccogene in 2023; AZD5004 / ECC5004) — a direct competitor to Lilly's orforglipron in the race for a convenient oral incretin.
- What safety findings are reported for Elecoglipron (AZD5004 / ECC5004)?
- Elecoglipron (AZD5004 / ECC5004) has a med risk profile in the database. Med (incretin-class GI: nausea, vomiting, diarrhea — dose-dependent) Legal status: Investigational (Phase 3 initiated -- Embold trial, n=4,500, recruiting since Jun 29 2026).
- What doses or routes are reported for Elecoglipron (AZD5004 / ECC5004)?
- Oral once daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Elecoglipron (AZD5004 / ECC5004) work?
- Once-daily oral non-peptide GLP-1 receptor agonist — delivers incretin appetite suppression and glycemic control as a pill rather than an injection
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.